PLATINUM-RESISTANT OVARIAN CANCER

This study is testing a three-part treatment for women whose ovarian cancer has returned and stopped responding to standard platinum-based chemotherapy. Doctors will collect a patient's own immune cells, grow and activate them in a lab, and then infuse them back alongside two oth…

This study is testing an experimental drug called CBX-12 for women whose ovarian cancer has stopped responding to platinum-based chemotherapy. It aims to see if the drug is safe and can shrink tumors. About 40 participants will receive one of two different doses every three weeks…

This is the first study in people testing a new cancer drug called MGC026. It aims to find a safe dose and see if the drug can help shrink tumors in adults with advanced solid tumors that have not responded to other treatments. The study will also check how the drug moves through…

This is the first human study of a new experimental cancer drug called HWK-007. Researchers are testing it in adults with advanced ovarian, endometrial, or non-small cell lung cancers that have stopped responding to standard treatments. The main goals are to find the safest dose …

This early-stage study is testing a new type of treatment for ovarian cancer that has come back and stopped responding to standard platinum-based chemotherapy. Researchers are collecting a patient's own immune cells, boosting them in a lab to create 'memory-like' natural killer (…

This is the first-ever study in people of a new targeted cancer drug called HWK-016. It aims to find a safe and effective dose for adults with advanced ovarian or endometrial cancer that has spread or come back. The study will test the drug alone and in combination with another c…

This early-stage trial is testing a new personalized cell therapy called OPB-101 for women with ovarian cancer that has stopped responding to standard platinum-based chemotherapy. Doctors will modify a patient's own immune cells in a lab to target the cancer and then infuse them …

This is the first study in people to test a new oral drug called NKT3964. It aims to see if the drug is safe and can help control advanced cancers that have spread and stopped responding to standard treatments. The study will enroll adults with specific advanced solid tumors, inc…

This study is testing an experimental immunotherapy drug called lorigerlimab for women with advanced ovarian and other gynecologic cancers that have stopped responding to standard platinum-based chemotherapy. About 60 participants will receive the drug through an IV every three w…

This is the first time researchers are testing a new drug called MEN2501 in people with ovarian cancer that has stopped responding to standard platinum-based chemotherapy. The study aims to find a safe dose, understand how the drug works in the body, and see if it can help contro…

This early-stage trial is testing whether a specially engineered virus called TILT-123, when combined with existing cancer drugs, is safe and potentially effective for women with advanced ovarian cancer that has stopped responding to standard platinum chemotherapy. The virus is d…

This early-stage trial is testing a new drug called CTIM-76 for people with advanced ovarian, testicular, or endometrial cancers that have stopped responding to standard treatments. The study will enroll 80 participants to determine safe dosage levels and see if the drug helps co…

This study is testing if a modified virus called Olvi-Vec, given directly into the abdomen, can help chemotherapy work better for women with ovarian cancer that has stopped responding to standard platinum drugs. Participants will be randomly assigned to receive either the virus f…